PVT1, a YAP1 dependent stress responsive lncRNA drives ovarian cancer metastasis and chemoresistance
K. Tabury, M. Monavarian, E. Listik, A. K. Shelton, A. S. Choi, R. Quintens, R. C. Arend, N. Hempel, C. R. Miller, B. Györrfy, K. Mythreye
Abstract
Metastatic growth of ovarian cancer cells into the peritoneal cavity requires adaptation to various cellular stress factors to facilitate cell survival and growth. Here we demonstrate the role of PVT1, one such stress induced long non-coding RNA, in ovarian cancer growth and metastasis. PVT1 is an amplified and overexpressed lncRNA in ovarian cancer with strong predictive value for survival and response to targeted therapeutics. We find that expression of PVT1 is regulated by ovarian tumor cells in response to cellular stress, particularly loss of cell-cell contacts and changes in matrix rigidity occurring in a YAP1 dependent manner. Induction of PVT1 promotes tumor cell survival, growth, and migration. Conversely, reducing PVT1 levels robustly abrogates metastatic behavior and tumor cell dissemination in cell lines and syngeneic transplantation models in vivo. We find that reducing PVT1 causes widespread transcriptome changes leading to alterations in cellular stress response and metabolic pathways including doxorubicin metabolism, which directly impacts chemosensitivity. Together, these findings implicate PVT1 as a promising therapeutic target to suppress metastasis and avoid chemoresistance in ovarian cancer. SUMMARY BLURBPVT1 is a stress-responsive IncRNA regulated by YAP1, leading to increased ovarian cancer metastasis and chemoresistance, making PVT1 a promising therapeutic target.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Metabolic plasticity increases evolvability and drives persistence to PARP inhibitor in ovarian cancer
Adriana Del Pino Herrera, Joon-Hyun Song, … Meghan C. Ferrall-Fairbanks·bioRxiv·Oct 8, 2025
- Engineered Extracellular Vesicles Enriched with the miR-214/199a Cluster Enhance the Efficacy of Chemotherapy for Ovarian Cancer
Weida Wang, Ayesha B. Alvero, … Yi Zhang·Molecular OncologyPeer-reviewed·Feb 13, 2026
- Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells.
Y. S. Kim, P. Gupta-Vallur, … N. Hempel·bioRxiv·Jun 13, 2019
- Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness
Z. Huang, O. Byrd, … S. K. Murphy·bioRxiv·Mar 30, 2023
- G6PD Inhibition Sensitizes Ovarian Cancer Cells to Oxidative Stress in the Metastatic Omental Microenvironment
- Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 Mediator kinase inhibition.
M. Monavarian, R. Rajkarnikar, … K. Mythreye·bioRxiv·Dec 4, 2023